Detalhe da pesquisa
1.
Caregiver-reported clinical characteristics and the burden associated with Kabuki syndrome.
Am J Med Genet A
; 182(7): 1592-1600, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32246746
2.
Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period.
Calcif Tissue Int
; 105(3): 271-284, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31165191
3.
Qualitative Research to Explore the Patient Experience of X-Linked Hypophosphatemia and Evaluate the Suitability of the BPI-SF and WOMAC® as Clinical Trial End Points.
Value Health
; 21(8): 973-983, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30098676
4.
Burosumab Improves Patient-Reported Outcomes in Adults With Tumor-Induced Osteomalacia: Mixed-Methods Analysis.
J Bone Miner Res
; 38(11): 1654-1664, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37578099
5.
Mania symptoms and HIV-risk behavior among adolescents in mental health treatment.
J Clin Child Adolesc Psychol
; 41(6): 803-10, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22540428
6.
A Qualitative Study to Characterize the Humanistic Burden of Kabuki Syndrome in the United States and Canada.
Adv Ther
; 39(1): 619-631, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34843084
7.
The Lifelong Impact of X-Linked Hypophosphatemia: Results From a Burden of Disease Survey.
J Endocr Soc
; 3(7): 1321-1334, 2019 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31259293
8.
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.
J Bone Miner Res
; 33(8): 1383-1393, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29947083
9.
Validation of a treatment satisfaction questionnaire in non-Hodgkin lymphoma: assessing the change from intravenous to subcutaneous administration of rituximab.
Patient Prefer Adherence
; 10: 1767-1776, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27695295
10.
Determining priority signs and symptoms for use as clinical outcomes assessments in trials including patients with malignant gliomas: Panel 1 Report.
Neuro Oncol
; 18 Suppl 2: ii1-ii12, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26989127
11.
Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.
J Clin Oncol
; 33(19): 2166-75, 2015 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26014298
12.
The development and psychometric evaluation of the emotional reactivity and numbing scale.
J Nerv Ment Dis
; 195(10): 830-6, 2007 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18043523